Reta peptide side effects most commonly include nausea, diarrhea, vomiting, constipation, and reduced appetite, according to published clinical trials. Reta, scientifically known as retatrutide (LY3437943), is an investigational triple hormone receptor agonist developed by Eli Lilly. Clinical research has also identified increased heart rate, skin sensitivity, and other potential safety concerns that require further evaluation.
Interest in retatrutide has expanded significantly due to its activity at three metabolic receptors: GLP-1, GIP, and glucagon. However, understanding its potential adverse effects is just as important as examining its experimental biological activity.
In 2026, Phase 3 trials provided additional evidence concerning retatrutide’s safety profile. Nevertheless, the compound remains investigational and is not FDA-approved for human use.
This article examines Reta peptide side effects, clinical trial safety data, potential risks, and important unanswered questions based on scientific research available through November 2026.
What Is Reta Peptide (Retatrutide)?
Reta is a shortened name for retatrutide, an experimental peptide being investigated for its effects on metabolic regulation.
Unlike compounds that activate only one or two metabolic receptors, retatrutide activates three:
- GLP-1 receptor: Involved in glucose regulation, insulin secretion, appetite signaling, and gastrointestinal activity.
- GIP receptor: Participates in insulin signaling and metabolic regulation.
- Glucagon receptor: Influences hepatic glucose metabolism and energy balance.
This combination has led researchers to describe retatrutide as a triple hormone receptor agonist.
Its multi-receptor activity is scientifically interesting, but it also makes careful safety evaluation necessary.
For a detailed explanation of its molecular mechanism, read Everything You Need to Know About Retatrutide.
What Are the Most Common Reta Peptide Side Effects?
The Phase 2 clinical trial published in The New England Journal of Medicine in 2023 included 338 adults with obesity or overweight and an associated weight-related condition.
Participants received investigational retatrutide or placebo over 48 weeks.
The researchers found that gastrointestinal adverse events were the most frequently reported side effects.
The following percentages represent adverse events reported among all 337 participants assigned to retatrutide, across the different treatment groups.
| Reported adverse event | Percentage of participants |
|---|---|
| Nausea | 27% |
| Decreased appetite | 18% |
| Diarrhea | 13% |
| Vomiting | 10% |
| Constipation | 9% |
| Fatigue | 7% |
| Early satiety | 5% |
These findings do not mean every participant will experience these reactions. Their frequency varied across treatment groups and study conditions.
The investigators reported that gastrointestinal events were generally mild to moderate and were more common at higher investigational doses.
Source: Jastreboff et al., 2023 — Triple-Hormone-Receptor Agonist Retatrutide for Obesity
1. Nausea and Vomiting
Nausea was the most frequently reported gastrointestinal adverse event in the Phase 2 obesity trial.
Approximately 27% of retatrutide-treated participants reported nausea, compared with 11% in the placebo group.
Vomiting occurred in approximately 10% of retatrutide-treated participants, compared with 1% of those receiving placebo.
Researchers observed that gastrointestinal events occurred particularly during periods of treatment escalation.
Retatrutide’s GLP-1 receptor activity may contribute to gastrointestinal effects through mechanisms involving appetite regulation and gastric function.
However, the precise contribution of each receptor pathway to these adverse effects requires further investigation.
2. Diarrhea and Constipation
Changes in gastrointestinal function were also documented.
In the Phase 2 trial, diarrhea was reported by approximately 13% of retatrutide-treated participants, while constipation was reported by approximately 9%.
These events occurred at different frequencies across treatment groups.
Newer findings from the Phase 3 TRIUMPH-2 trial, published in 2026, also identified diarrhea and nausea among the most commonly reported adverse events in participants with obesity and type 2 diabetes.
Diarrhea occurred in 27% to 34% of participants across the retatrutide treatment groups, compared with 13% in the placebo group.
These findings reinforce the importance of gastrointestinal safety monitoring during clinical development.
Source: TRIUMPH-2 Phase 3 Trial — PubMed
3. Increased Heart Rate
One of the more distinctive safety findings associated with retatrutide involves heart rate.
The 2023 Phase 2 trial reported dose-dependent increases in heart rate.
These increases generally peaked around week 24 before declining later during the observation period.
Because retatrutide activates glucagon receptors in addition to GIP and GLP-1 receptors, researchers are investigating how its combined signaling affects cardiovascular physiology.
The available findings do not establish the long-term cardiovascular safety of retatrutide.
Larger studies and longer observation periods are important for evaluating these effects.
4. Skin Sensitivity and Dysesthesia
An additional finding involved unusual skin sensations.
In the Phase 2 trial, cutaneous hyperesthesia and skin sensitivity were reported by approximately 7% of participants receiving retatrutide, compared with 1% receiving placebo.
Hyperesthesia refers to increased sensitivity to sensory stimulation.
Dysesthesia describes abnormal or unpleasant sensations, which may include burning, tingling, or discomfort.
The Phase 3 TRIUMPH-2 study also reported dysesthesia more frequently among retatrutide-treated participants than among those receiving placebo.
These findings have drawn scientific attention because the mechanisms underlying these sensory effects are not yet fully understood.
5. Fatigue and Reduced Appetite
Fatigue was reported by approximately 7% of retatrutide-treated participants in the Phase 2 trial.
Reduced appetite was reported by approximately 18%.
Although appetite-related signaling is part of the compound’s investigated biological activity, decreased appetite was also recorded as an adverse event.
Researchers must distinguish between intended pharmacological effects and outcomes that may become clinically undesirable under particular circumstances.
Are There Serious Reta Peptide Side Effects?
Although gastrointestinal effects were most common, clinical studies have also examined potentially serious adverse events.
In the Phase 2 obesity trial, serious adverse events were reported in approximately 4% of participants receiving retatrutide and 4% receiving placebo.
The study reported one serious case of acute pancreatitis and several gallbladder-related events among participants receiving retatrutide.
The investigators also observed some changes in pancreatic enzyme measurements.
These events require careful interpretation because a reported adverse event is not automatically proof that the investigational compound caused it.
Other areas requiring continued evaluation include:
- Pancreatic and gallbladder safety.
- Cardiovascular effects and changes in heart rate.
- Low blood pressure and related symptoms.
- Abnormal skin sensations.
- Severe gastrointestinal reactions.
- Potential interactions with other medications.
- Longer-term safety outcomes in different patient populations.
Severe or persistent abdominal pain, repeated vomiting, fainting, or signs of an allergic reaction warrant prompt medical assessment in anyone exposed to an investigational medication.
What Do the Latest 2026 Retatrutide Clinical Trials Show?
The 2026 Phase 3 TRIUMPH research program expanded the available evidence on retatrutide’s safety and effectiveness.
In the TRIUMPH-1 obesity study, treatment-emergent adverse events occurred in approximately 87% to 89.2% of participants assigned to retatrutide, compared with 80.7% receiving placebo.
Serious adverse events were reported in 7.7% to 10.5% of the retatrutide groups and 5.5% of the placebo group.
Discontinuation due to adverse events occurred in 4% to 11% of participants receiving retatrutide.
The most commonly reported reasons for treatment discontinuation included gastrointestinal adverse events.
Investigators also monitored events such as dysesthesia, injection-site reactions, and hypotension.
The trial’s results add important information to the developing safety profile, but they do not remove the need for longer-term research or regulatory review.
Source: Eli Lilly — TRIUMPH-1 Phase 3 Trial Findings
Does the Risk of Reta Peptide Side Effects Increase at Higher Doses?
Clinical trials have identified dose-related differences in several adverse events.
In the Phase 2 obesity study, gastrointestinal effects were generally more frequent in the higher-dose treatment groups.
The investigators also found that participants assigned to different starting-dose protocols experienced different rates of gastrointestinal events.
These findings help researchers understand exposure-response relationships and the compound’s tolerability during pharmaceutical development.
They should not be interpreted as self-administration or dosing recommendations.
Retatrutide has no FDA-approved dosing schedule for public use, and clinical-trial procedures should not be replicated with unapproved research materials.
Are There Long-Term Side Effects of Retatrutide?
Long-term safety remains an important research question.
Although Phase 3 studies have extended the observation period beyond the original Phase 2 trial, some potential risks may only become clearer through larger populations and longer follow-up.
Scientists continue to investigate:
- Long-term cardiovascular outcomes.
- Pancreatic and gallbladder safety.
- The persistence of altered skin sensations.
- Effects of sustained metabolic receptor activation.
- Safety in people with different underlying medical conditions.
- Adverse-event patterns following extended exposure.
The absence of a particular adverse event in a clinical trial does not establish that the event is impossible.
Similarly, an adverse event reported during a trial does not necessarily demonstrate causation.
This distinction is fundamental to clinical safety research.
Is Reta Peptide FDA Approved in 2026?
No. As of November 2026, retatrutide remains an investigational compound and has not received FDA approval.
Eli Lilly continues to study retatrutide through its clinical development program.
The company has also warned that products offered outside authorized clinical studies may differ from the pharmaceutical material used in its trials.
Materials marketed for laboratory research are not interchangeable with clinical-trial medications.
Their identity, composition, quality, and suitability cannot be established solely by referring to published results obtained using pharmaceutical-grade investigational products.
For official regulatory and development information, see Eli Lilly’s Retatrutide Research Overview.
Retatrutide Research at Neuro Peptide
At Neuro Peptide, retatrutide is listed as a laboratory research compound intended for scientific investigation of metabolic signaling pathways.
Researchers studying retatrutide may be interested in its triple receptor mechanism, molecular properties, and published clinical findings.
Neuro Peptide’s catalog includes Retatrutide 10mg for Laboratory Research, with product information and batch-specific analytical documentation.
This research material is not the investigational pharmaceutical formulation used in Eli Lilly’s clinical trials and is not intended for human or veterinary administration.
Researchers should evaluate analytical documentation and relevant laboratory safety requirements before handling experimental compounds.
Frequently Asked Questions About Reta Peptide Side Effects
What is the most common side effect of Reta peptide?
Nausea was the most frequently reported gastrointestinal adverse event in the 2023 Phase 2 obesity trial, occurring in approximately 27% of retatrutide-treated participants.
Does Reta peptide cause diarrhea?
Diarrhea has been reported in both Phase 2 and Phase 3 clinical studies. The reported frequency varied according to the trial population and treatment group.
Can retatrutide increase heart rate?
Yes. The Phase 2 obesity trial observed dose-dependent increases in heart rate, particularly during the earlier portion of the study. The long-term clinical significance requires continued investigation.
Does Reta peptide cause skin sensitivity?
Skin sensitivity and dysesthesia have been reported during retatrutide clinical trials. The underlying mechanisms are not fully established.
Are retatrutide side effects permanent?
Current research does not establish that the commonly reported adverse effects are permanent. However, longer-term data are necessary to characterize persistent or delayed effects.
Is retatrutide safer than semaglutide or tirzepatide?
The available evidence does not support a definitive overall safety ranking between these compounds. They have different receptor activity and have been evaluated in different clinical trials and populations. Direct comparative studies are needed for reliable conclusions.
Can Reta peptide cause pancreatitis?
A serious case of acute pancreatitis was reported in the Phase 2 obesity trial. This does not establish how often retatrutide causes pancreatitis or whether the reported event was causally related. Pancreatic safety remains an important area of investigation.
Is Reta peptide safe for human consumption?
Retatrutide is not FDA-approved for human use. Its safety continues to be evaluated in controlled clinical studies, and research-grade products should not be used for self-administration.
Final Thoughts: Understanding Reta Peptide Side Effects
Reta peptide side effects are predominantly gastrointestinal, but clinical studies have also identified cardiovascular, sensory, and other safety findings that warrant continued investigation.
The most commonly documented adverse events include nausea, diarrhea, vomiting, constipation, and decreased appetite.
Research published in 2023 and 2026 has expanded scientific understanding of retatrutide, yet important questions remain regarding long-term safety and uncommon adverse outcomes.
For researchers, understanding these findings provides valuable context for investigating triple receptor agonist biology.
Learn more about retatrutide’s structure and mechanism in Neuro Peptide’s Retatrutide Research Guide.
Scientific References
- Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2301972
- Retatrutide in Adults with Obesity and Type 2 Diabetes (TRIUMPH-2). Phase 3 randomized clinical trial, 2026. https://pubmed.ncbi.nlm.nih.gov/42810372/
- Eli Lilly. (2026). The First Phase 3 Obesity Study of Retatrutide (TRIUMPH-1). https://www.lilly.com/hcp/congresses/ada-2026/dv039292-triumph-1
- Eli Lilly. (2026). What to Know About Retatrutide. https://www.lilly.com/news/stories/what-to-know-about-retatrutide
Scientific disclaimer: This article is provided for educational and scientific research purposes only. Retatrutide is investigational and has not been approved by the FDA. Neuro Peptide research materials are not intended for human or veterinary use. The content does not provide medical advice, treatment recommendations, or instructions for using experimental compounds.